Pay in 4 interest-free payments of $5.64 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Comparative Long-Term Outlook Neither Retatrutide nor Survodutide has long-term data beyond their Phase 2 and early Phase 3 trial durations
Nearly one-third of participants lost 20% or more of their body weight
The cytokine Growth Differentiation Factor-15 and skeletal muscle health: portrait of an emerging widely applicable disease biomarker
Medicines and Healthcare Products Regulatory Agency
US$ 21.30
US$ 26.34
US$ 20.74
US$ 21.60
US$ 26.75
US$ 21.96
US$ 21.16
US$ 26.20
